Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega 3 for Asymmetrical Intrauterine Growth Restriction
NCT02696577Phase 2Completed
- Sponsor
- Assiut University
- Start
- Mar 2015
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of MAT9001 in intrauterine growth restriction (IUGR), sponsored by Assiut University. Primary endpoint: Estimated fetal weight at 1 year. Started Mar 2015; status: completed.
02
Drugs
MAT9001
03
Conditions
intrauterine growth restriction (IUGR)
Beyond the preview
Go deeper on NCT02696577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02696577.